UBS AG reissued their neutral rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a report published on Thursday morning, www.flashratings.com reports. They currently have a $19.00 target price on the stock.

Several other research analysts have also commented on the stock. Gabelli restated a buy rating on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, September 13th. BidaskClub upgraded shares of Teva Pharmaceutical Industries Limited from a strong sell rating to a sell rating in a report on Wednesday, September 13th. Oppenheimer Holdings, Inc. restated a hold rating on shares of Teva Pharmaceutical Industries Limited in a report on Monday, September 11th. Jefferies Group LLC decreased their price objective on shares of Teva Pharmaceutical Industries Limited from $21.00 to $18.50 and set a hold rating for the company in a report on Tuesday, September 12th. Finally, Cantor Fitzgerald set a $17.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a hold rating in a report on Monday, September 11th. Five equities research analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Hold and an average price target of $31.42.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 18.10 on Thursday. Teva Pharmaceutical Industries Limited has a 1-year low of $15.22 and a 1-year high of $52.01. The company’s market capitalization is $18.39 billion. The firm has a 50-day moving average of $19.00 and a 200 day moving average of $28.55.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). The firm had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The company’s quarterly revenue was up 12.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.25 EPS. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/09/18/teva-pharmaceutical-industries-limited-teva-stock-rating-reaffirmed-by-ubs-ag.html.

The company also recently announced a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were paid a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 1.88%. The ex-dividend date was Friday, August 25th. Teva Pharmaceutical Industries Limited’s payout ratio is -15.36%.

Several institutional investors have recently added to or reduced their stakes in the company. WFG Advisors LP raised its position in shares of Teva Pharmaceutical Industries Limited by 2,650.1% during the second quarter. WFG Advisors LP now owns 29,784 shares of the company’s stock valued at $989,000 after buying an additional 28,701 shares during the last quarter. Oak Associates Ltd. OH raised its position in shares of Teva Pharmaceutical Industries Limited by 0.6% during the second quarter. Oak Associates Ltd. OH now owns 379,924 shares of the company’s stock valued at $12,621,000 after buying an additional 2,114 shares during the last quarter. Cetera Investment Advisers bought a new stake in shares of Teva Pharmaceutical Industries Limited during the second quarter valued at approximately $373,000. Sterneck Capital Management LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 5.4% during the second quarter. Sterneck Capital Management LLC now owns 131,907 shares of the company’s stock valued at $4,382,000 after buying an additional 6,702 shares during the last quarter. Finally, Northern Cross LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 14.0% during the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after buying an additional 2,184,172 shares during the last quarter. Hedge funds and other institutional investors own 56.87% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.